In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp

Antimicrob Agents Chemother. 2008 Apr;52(4):1529-32. doi: 10.1128/AAC.01097-07. Epub 2008 Jan 28.

Abstract

The in vitro activity of amphotericin B in combination with micafungin was evaluated against 115 isolates representing seven species of Candida. Overall, the percentages of synergistic interactions were 50% and 20% when the MIC-2 (lowest drug concentration to cause a prominent reduction in growth) and MIC-0 (lowest drug concentration to cause 100% growth inhibition) end point criteria, respectively, were used. Antagonism was not observed. Some of the interactions were confirmed by time-kill assays.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / pharmacology*
  • Antifungal Agents / pharmacology*
  • Candida / classification*
  • Candida / drug effects*
  • Candida / growth & development
  • Candida / isolation & purification
  • Drug Synergism
  • Drug Therapy, Combination
  • Echinocandins / pharmacology*
  • Humans
  • Lipopeptides
  • Lipoproteins / pharmacology*
  • Micafungin
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Lipoproteins
  • Amphotericin B
  • Micafungin